down arrow

Catalent, Inc.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals: Major
  • ISIN: US1488061029
USD
63.48
0.00 (0.00%)

Dec 19

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

58.3063.50
Valuation
Technical
Day's Volume

CASH

0

Shareholding (Sep 2024)

FII

34.01%

Held by 310 FIIs

DII

15.4%

Held by 77 DIIs

Promoter

0.76%

How big is Catalent, Inc.?

22-Jun-2025

As of Dec 19, Catalent, Inc. has a market capitalization of $11.52 billion, with net sales of $4.42 billion and a net profit of -$413 million over the latest four quarters.

Market Cap: As of Dec 19, Catalent, Inc. has a market capitalization of 11,522.36 million, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Catalent, Inc. reported net sales of 4,422.00 million and a net profit of -413.00 million.<BR><BR>Balance Sheet Snapshot: As of June 24, the company reported shareholder's funds of 3,604.00 million and total assets of 9,753.00 million.

Read More

What does Catalent, Inc. do?

22-Jun-2025

Catalent, Inc. specializes in delivery technologies and development solutions for pharmaceuticals, biologics, and health products, with a market cap of approximately $11.5 billion. As of September 2024, it reported net sales of $1.023 billion but a net loss of $129 million.

Overview: <BR>Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products in the Pharmaceuticals: Major industry, with a market capitalization in the mid-cap bracket.<BR><BR>Financial Snapshot: <BR>Net Sales: 1,023 Million (Quarterly Results - Sep 2024) <BR>Net Profit: -129 Million (Quarterly Results - Sep 2024) <BR>Market cap: USD 11,522.36 Million (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 9,934.82% <BR>Debt Equity: 1.30 <BR>Return on Equity: -5.80% <BR>Price to Book: 3.25<BR><BR>Contact Details: <BR>Address: 14 Schoolhouse Rd, SOMERSET NJ: 08873-1213 <BR>Tel: 1 732 5376200 <BR>Fax: 1 732 5376480 <BR>Website: https://www.catalent.com/

Read More

Who are in the management team of Catalent, Inc.?

22-Jun-2025

As of March 2022, the management team of Catalent, Inc. includes John Chiminski as Chairman and CEO, with Jack Stahl as Lead Independent Director and independent directors Madhavan Balachandran, J. Martin Carroll, Rolf Classon, and Rosemary Crane.

As of March 2022, the management team of Catalent, Inc. includes Mr. John Chiminski, who serves as the Chairman of the Board and Chief Executive Officer. Additionally, the Board of Directors features Mr. Jack Stahl as the Lead Independent Director, along with independent directors Mr. Madhavan Balachandran, Mr. J. Martin Carroll, Mr. Rolf Classon, and Ms. Rosemary Crane.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals: Major

stock-summary
Market cap

USD 11,522 Million (Mid Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

9,934.82%

stock-summary
Debt Equity

1.30

stock-summary
Return on Equity

-5.80%

stock-summary
Price to Book

3.25

Revenue and Profits:
Net Sales:
1,023 Million
(Quarterly Results - Sep 2024)
Net Profit:
-129 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
5.61%
0%
5.61%
6 Months
15.27%
0%
15.27%
1 Year
42.2%
0%
42.2%
2 Years
44.67%
0%
44.67%
3 Years
-49.37%
0%
-49.37%
4 Years
-39.54%
0%
-39.54%
5 Years
14.9%
0%
14.9%

Catalent, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
10.94%
EBIT Growth (5y)
-12.08%
EBIT to Interest (avg)
3.50
Debt to EBITDA (avg)
4.66
Net Debt to Equity (avg)
1.30
Sales to Capital Employed (avg)
0.50
Tax Ratio
19.02%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
6.31%
ROE (avg)
6.37%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.25
EV to EBIT
104.09
EV to EBITDA
25.01
EV to Capital Employed
1.98
EV to Sales
3.65
PEG Ratio
NA
Dividend Yield
9934.82%
ROCE (Latest)
1.90%
ROE (Latest)
-5.80%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Bullish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 133 Schemes (49.83%)

Foreign Institutions

Held by 310 Foreign Institutions (34.01%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2024 is -21.37% vs 21.14% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2024 is -660.87% vs 122.77% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,023.00",
          "val2": "1,301.00",
          "chgp": "-21.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "108.00",
          "val2": "290.00",
          "chgp": "-62.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "60.00",
          "val2": "65.00",
          "chgp": "-7.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-75.00",
          "val2": "-52.00",
          "chgp": "-44.23%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-129.00",
          "val2": "23.00",
          "chgp": "-660.87%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-4.90%",
          "val2": "123.00%",
          "chgp": "-12.79%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2024 is 2.77% vs -11.22% in Jun 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2024 is -307.42% vs -153.00% in Jun 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'24",
        "Jun'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4,381.00",
          "val2": "4,263.00",
          "chgp": "2.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "634.00",
          "val2": "665.00",
          "chgp": "-4.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "254.00",
          "val2": "186.00",
          "chgp": "36.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-894.00",
          "val2": "-406.00",
          "chgp": "-120.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1,043.00",
          "val2": "-256.00",
          "chgp": "-307.42%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "33.10%",
          "val2": "57.00%",
          "chgp": "-2.39%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Sep'24 - QoQstock-summary
Sep'24
Jun'24
Change(%)
Net Sales
1,023.00
1,301.00
-21.37%
Operating Profit (PBDIT) excl Other Income
108.00
290.00
-62.76%
Interest
60.00
65.00
-7.69%
Exceptional Items
-75.00
-52.00
-44.23%
Consolidate Net Profit
-129.00
23.00
-660.87%
Operating Profit Margin (Excl OI)
-4.90%
123.00%
-12.79%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Sep 2024 is -21.37% vs 21.14% in Jun 2024

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Sep 2024 is -660.87% vs 122.77% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Jun'24stock-summary
Jun'24
Jun'23
Change(%)
Net Sales
4,381.00
4,263.00
2.77%
Operating Profit (PBDIT) excl Other Income
634.00
665.00
-4.66%
Interest
254.00
186.00
36.56%
Exceptional Items
-894.00
-406.00
-120.20%
Consolidate Net Profit
-1,043.00
-256.00
-307.42%
Operating Profit Margin (Excl OI)
33.10%
57.00%
-2.39%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Jun 2024 is 2.77% vs -11.22% in Jun 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Jun 2024 is -307.42% vs -153.00% in Jun 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Catalent, Inc. stock-summary
stock-summary
Catalent, Inc.
Pharmaceuticals: Major
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.
Company Coordinates stock-summary
Company Details
14 Schoolhouse Rd , SOMERSET NJ : 08873-1213
stock-summary
Tel: 1 732 5376200
stock-summary
https://www.catalent.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."